株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

FIT Biotech Oyjの製品パイプライン分析

FIT Biotech Oy - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 251666
出版日 ページ情報 英文 27 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
FIT Biotech Oyjの製品パイプライン分析 FIT Biotech Oy - Product Pipeline Review - 2015
出版日: 2015年02月28日 ページ情報: 英文 27 Pages
概要

当レポートでは、FIT Biotech Oyjにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

FIT Biotech Oyjの基本情報

FIT Biotech Oyjの概要

  • 主要情報
  • 企業情報

FIT Biotech Oyj:R&Dの概要

  • 主な治療範囲

FIT Biotech Oyj:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

FIT Biotech Oyj:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

FIT Biotech Oyj:薬剤プロファイル

  • FIT-06
  • GTU-Nef
  • FP6 TBVAC
  • マラリアワクチン
  • デング熱用ワクチン

FIT Biotech Oyj:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別

FIT Biotech Oyj:最近のパイプライン動向

FIT Biotech Oyj:休止中のプロジェクト

FIT Biotech Oyj:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06838CDB

Summary

Global Markets Direct's, 'FIT Biotech Oy - Product Pipeline Review - 2015', provides an overview of the FIT Biotech Oy's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of FIT Biotech Oy's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of FIT Biotech Oy including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of FIT Biotech Oy's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the FIT Biotech Oy's pipeline products

Reasons to buy

  • Evaluate FIT Biotech Oy's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of FIT Biotech Oy in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the FIT Biotech Oy's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of FIT Biotech Oy and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of FIT Biotech Oy
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of FIT Biotech Oy and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • FIT Biotech Oy Snapshot
    • FIT Biotech Oy Overview
    • Key Information
    • Key Facts
  • FIT Biotech Oy - Research and Development Overview
    • Key Therapeutic Areas
  • FIT Biotech Oy - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • FIT Biotech Oy - Pipeline Products Glance
    • FIT Biotech Oy - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • FIT Biotech Oy - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • FIT Biotech Oy - Drug Profiles
    • FIT-06
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FIT-06 + LIPO-5
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tuberculosis vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dengue vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ebola vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • malaria vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • FIT Biotech Oy - Pipeline Analysis
    • FIT Biotech Oy - Pipeline Products by Route of Administration
    • FIT Biotech Oy - Pipeline Products by Molecule Type
  • FIT Biotech Oy - Recent Pipeline Updates
  • FIT Biotech Oy - Dormant Projects
  • FIT Biotech Oy - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • FIT Biotech Oy, Key Information
  • FIT Biotech Oy, Key Facts
  • FIT Biotech Oy - Pipeline by Indication, 2015
  • FIT Biotech Oy - Pipeline by Stage of Development, 2015
  • FIT Biotech Oy - Monotherapy Products in Pipeline, 2015
  • FIT Biotech Oy - Combination Treatment Modalities in Pipeline, 2015
  • FIT Biotech Oy - Phase II, 2015
  • FIT Biotech Oy - Preclinical, 2015
  • FIT Biotech Oy - Discovery, 2015
  • FIT Biotech Oy - Pipeline by Route of Administration, 2015
  • FIT Biotech Oy - Pipeline by Molecule Type, 2015
  • FIT Biotech Oy - Recent Pipeline Updates, 2015
  • FIT Biotech Oy - Dormant Developmental Projects,2015
  • FIT Biotech Oy, Other Locations

List of Figures

  • FIT Biotech Oy - Pipeline by Top 10 Indication, 2015
  • FIT Biotech Oy - Pipeline by Stage of Development, 2015
  • FIT Biotech Oy - Monotherapy Products in Pipeline, 2015
  • FIT Biotech Oy - Pipeline by Top 10 Route of Administration, 2015
  • FIT Biotech Oy - Pipeline by Top 10 Molecule Type, 2015
Back to Top